{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:52:41Z","timestamp":1792623161435,"version":"4.5.0"},"reference-count":45,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To identify macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (sJIA) undergoing tocilizumab (TCZ) treatment, and to confirm laboratory marker changes and responses to treatment in patients with MAS receiving TCZ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>In Japan, 394 patients with sJIA were registered in an all-patient registry surveillance of TCZ as of January 15, 2012. TCZ (8 mg\/kg) was administered every 2 weeks to patients with sJIA. MAS, hemophagocytic lymphohistiocytosis, or Epstein-Barr virus\u2013associated hemophagocytic syndrome (EB-VAHS) was reported in 23 of these patients (25 events). The Safety Evaluation Committee of Tocilizumab for JIA reviewed these cases and clinically evaluated the data and laboratory findings using their own therapeutic experience. Events were categorized into 4 groups: definitive MAS, probable MAS, EB-VAHS, and non-MAS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The committee\u2019s review revealed 3 events of definitive MAS in 3 patients, 12 events of probable MAS in 11 patients, 2 events of EB-VAHS in 2 patients, and 8 events of non-MAS in 8 patients. There were 2 patients who developed 2 events: 2 events in 1 patient were classified into definitive MAS and probable MAS, and 2 events in another patient were classified into probable MAS. In patients with definitive or probable MAS, common clinical manifestations and laboratory findings of MAS were observed. Changes in laboratory data observed in patients with EB-VAHS were similar to those observed in patients with MAS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>These results suggest that the clinical\/laboratory features in the course of MAS appear to be similar among patients regardless of whether TCZ is administered. Similarities in the pathophysiological background of MAS and EB-VAHS were also suggested.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.140288","type":"journal-article","created":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T20:09:16Z","timestamp":1424030956000},"page":"712-722","source":"Crossref","is-referenced-by-count":91,"title":["Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab"],"prefix":"10.3899","volume":"42","author":[{"given":"Shumpei","family":"Yokota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokata","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Daimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Minota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"2018112909340798000_42.4.712.1","doi-asserted-by":"crossref","unstructured":"Cassidy JT Petty RE . Juvenile idiopathic arthritis. In: Cassidy JT Petty RE Laxer R Lindsley C eds. Textbook of pediatric rheumatology, 6th ed. Philadelphia: WB Saunders; 2011:211\u2013314.","DOI":"10.1016\/B978-1-4160-6581-4.10013-5"},{"key":"2018112909340798000_42.4.712.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60244-4"},{"key":"2018112909340798000_42.4.712.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340912"},{"key":"2018112909340798000_42.4.712.4","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:28:3:231"},{"key":"2018112909340798000_42.4.712.5","doi-asserted-by":"publisher","DOI":"10.1136\/adc.85.5.421"},{"key":"2018112909340798000_42.4.712.6","first-page":"487","article-title":"[A case of macrophage activation syndrome developed with systemic juvenile idiopathic arthritis]","volume":"37","author":"Imagawa","year":"1997","journal-title":"Ryumachi"},{"key":"2018112909340798000_42.4.712.7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00832010"},{"key":"2018112909340798000_42.4.712.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2018112909340798000_42.4.712.9","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.41"},{"key":"2018112909340798000_42.4.712.10","unstructured":"Pharmaceuticals and Medical Devices Agency, Japan. [Actemra for intravenous infusion. Japanese product information, Tokyo]. [Article in Japanese; Internet. Accessed January 9, 2015.] Available from: chugai-pharm.jp\/hc\/ss\/pr\/drug\/act_via0080\/pi\/index.html"},{"key":"2018112909340798000_42.4.712.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2018112909340798000_42.4.712.12","unstructured":"US Food Drug Administration . Prescribing information of ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use. [Internet. Accessed December 23, 2014.] Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf."},{"key":"2018112909340798000_42.4.712.13","unstructured":"European Medicines Agency . RoActemra: EPAR- Product Information. [Internet. Accessed December 23, 2014.] Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000955\/WC500054890.pdf."},{"key":"2018112909340798000_42.4.712.14","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909340798000_42.4.712.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100996"},{"key":"2018112909340798000_42.4.712.16","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2012.3"},{"key":"2018112909340798000_42.4.712.17","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1128\/MCB.18.11.6353","article-title":"The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release","volume":"18","author":"Bradham","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2018112909340798000_42.4.712.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70160-9"},{"key":"2018112909340798000_42.4.712.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1023-z"},{"key":"2018112909340798000_42.4.712.20","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e3181a1ae08"},{"key":"2018112909340798000_42.4.712.21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.797"},{"key":"2018112909340798000_42.4.712.22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57158"},{"key":"2018112909340798000_42.4.712.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-008-0115-3"},{"key":"2018112909340798000_42.4.712.24","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32832f1445"},{"key":"2018112909340798000_42.4.712.25","first-page":"459","article-title":"The incidence of macrophage activation syndrome in children with rheumatic disorders","volume":"63","author":"Moradinejad","year":"2011","journal-title":"Minerva Pediatr"},{"key":"2018112909340798000_42.4.712.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"2018112909340798000_42.4.712.27","first-page":"623","article-title":"Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis","volume":"31","author":"Sawar","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909340798000_42.4.712.28","first-page":"635","article-title":"Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis","volume":"11","author":"N\u00e1dia","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"2018112909340798000_42.4.712.29","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181a4f459"},{"key":"2018112909340798000_42.4.712.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.30128"},{"key":"2018112909340798000_42.4.712.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100655"},{"key":"2018112909340798000_42.4.712.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.11.1285"},{"key":"2018112909340798000_42.4.712.33","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200309000-00011"},{"key":"2018112909340798000_42.4.712.34","doi-asserted-by":"publisher","DOI":"10.1186\/cc11256"},{"key":"2018112909340798000_42.4.712.35","doi-asserted-by":"publisher","DOI":"10.1159\/000083450"},{"key":"2018112909340798000_42.4.712.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2005.02.001"},{"key":"2018112909340798000_42.4.712.37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2119\/molmed.2010.00146","article-title":"Novel aspects of fibrin(ogen) fragments during inflammation","volume":"17","author":"Jennewein","year":"2011","journal-title":"Mol Med"},{"key":"2018112909340798000_42.4.712.38","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200205001-00008"},{"key":"2018112909340798000_42.4.712.39","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-22"},{"key":"2018112909340798000_42.4.712.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3413"},{"key":"2018112909340798000_42.4.712.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255174"},{"key":"2018112909340798000_42.4.712.42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20102538"},{"key":"2018112909340798000_42.4.712.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.03.022"},{"key":"2018112909340798000_42.4.712.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.20198"},{"key":"2018112909340798000_42.4.712.45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg074"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T19:24:20Z","timestamp":1566329060000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,1]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.3899\/jrheum.140288"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140288","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}